Switch Language
Alt tag
Bayer Logo Bayer Logo Bayer Logo

Welcome to Thrombosis Adviser

A Venous & Arterial Thrombosis Resource

Latest in Thrombosis

ESC 2022 Congress Highlights
ESC 2022 Congress Highlights
International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022
International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022
International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter
International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter
Your older patients with atrial fibrillation: Are you missing the broader picture?
Your older patients with atrial fibrillation: Are you missing the broader picture?

Latest in Thrombosis

2020_2_04_TA_ESC_2020_congress
Thrombosis Adviser at the European Society of Cardiology Congress 2020
Study teaser image
Paediatric patients with VTE: Protecting the most challenging population
Study teaser image
Thrombosis Adviser at the European Society of Cardiology Congress 2019
Study teaser image
Making connections: Stroke risk in patients with multiple co-morbidities

Latest in Thrombosis tb

2020_2_04_TA_ESC_2020_congress
Thrombosis Adviser at the European Society of Cardiology Congress 2020
Study teaser image
Paediatric patients with VTE: Protecting the most challenging population
Study teaser image
Thrombosis Adviser at the European Society of Cardiology Congress 2019
Study teaser image
Making connections: Stroke risk in patients with multiple co-morbidities

Listen to the Thrombosis Adviser Podcast Series

Going one step further: Renal preservation in patients with artial fibrillation 

Find out why renal decline is an important issue for patients with AF and how they can be protected

Approval code: PP-M_RIV-ALL-0104-1

Check out our story
Renal preservation

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

Sign up now!

Aspirin, Einstein
Choice and long-term
VTE treatment

YYMMDD Author/Uploaded by

Professor Paolo Prandoni looks at the role of ASA in extended VTE treatment and discusses the recent EINSTEIN CHOICE study, which compared two doses of rivaroxaban to ASA for extended VTE treatment.

Approval number PP-XAR-ALL-1747-1

Latest in Thrombosis

ThrombosisAdviser at
the European Society of
Cardiology Congress 2019

The European Society of Cardiology (ESC) congress is the largest cardio-vascular congress in the world. This year’s event also included the World Congress of Cardiology and attracted over 30,000 delegates, who gathered at the Paris Expo Porte de Versailles to participate in a programme of over 500 different sessions across the full spectrum of cardiovascular medicine. As ever, a large amount of the data and discussion focused on prevention of stroke in patients with atrial fibrillation (AF), reflecting the huge burden of this disease around the world.

Read more
Alt tag

Aspirin, Einstein
Choice and long-term
VTE treatment

YYMMDD Author/Uploaded by

Professor Paolo Prandoni looks at the role of ASA in extended VTE treatment and discusses the recent EINSTEIN CHOICE study, which compared two doses of rivaroxaban to ASA for extended VTE treatment.

Approval number PP-XAR-ALL-1747-1

Join the conversation!

Thrombosis Connection, A Healthcare Professionals’ Forum welcomes individuals interested in sharing, developing and fostering innovative solutions in the field of thrombosis.